ACR24 IL-17 Topic Panel Advancing Care with IL-17 Pathway Insights
Dec 5, 2024
auto_awesome
Brian Joros, a faculty expert in rheumatology at Northwestern University, and Peter Nash from Griffith University in Brisbane join the discussion. They dive into breakthrough advancements in targeting the IL-17 pathway for rheumatic diseases. Insights from the ACR Annual Meeting reveal impressive MRI remission rates with bemikizumab for ankylosing spondylitis. The duo also explores innovations in psoriatic arthritis treatments, addressing effectiveness, safety, and the nuances of treatment switches during flare-ups, making a case for the evolution of IL-17 therapies.
Bemikizumab significantly enhances MRI remission rates and reduces structural damage in ankylosing spondylitis by targeting the IL-17 pathway.
Sonolocumab shows promising efficacy in treating psoriatic arthritis, indicating a strong potential as a new IL-17 inhibitor option for patients.
Deep dives
Clinical Efficacy of Bemikizumab
The efficacy of bemikizumab, a novel monoclonal antibody that targets IL-17A and IL-17F, was highlighted in the context of imaging outcomes for patients with ankylosing spondylitis. During the B-Mobile 1 and 2 trials, a significant proportion of both radiographic and non-radiographic patients achieved MRI remission by week 16, with rates approaching 75-80% by week 52 for those who had consistently received the treatment. The study also indicated marked reductions in structural damage, such as erosions, in patients treated with bemikizumab when compared to placebo groups. These findings suggest a promising role for bemikizumab not only in providing symptomatic relief but also in potentially modifying the course of the disease from an imaging standpoint.
Exploration of Sonolocumab
Another promising candidate discussed was sonolocumab, a dual IL-17A and IL-17F inhibitor presented in phase two trials for psoriatic arthritis. The data demonstrated a notable increase in patient responses over a 24-week period, highlighting that around 59% of participants achieved ACR50, a significant improvement from 37% at week 12. Other endpoints, such as minimal disease activity, also showed encouraging results, with a progression from 44% to 62% achievement at the same intervals. This advancement indicates that sonolocumab could be a viable addition to the growing repertoire of IL-17 inhibitors, particularly in terms of efficacy and patient safety.
Safety Profile Comparisons in IL-17 Inhibitors
The discussion included a thorough examination of the safety profiles of various IL-17 inhibitors, particularly bemikizumab and its competitors. Data suggested that the incidence of serious infections was relatively low, comparable to untreated patients, which speaks to the overall safety of this class of drugs. Concerns such as the incidence of oral thrush and inflammatory bowel disease were acknowledged; however, these issues appear manageable and relatively uncommon. The aggregate evidence points toward a favorable safety advantage for IL-17 inhibitors over traditional TNF inhibitors, which may influence treatment decisions, especially in patients with complex rheumatologic needs.
Discover the latest advancements in targeting the IL-17 pathway from the ACR Annual Meeting! This expert-led panel will delve into groundbreaking research and therapeutic strategies for managing rheumatic diseases.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
